JP7644151B2 - 抗ｐｄ－１抗体および融合タンパク質 - Google Patents

抗ｐｄ－１抗体および融合タンパク質 Download PDF

Info

Publication number
JP7644151B2
JP7644151B2 JP2022578618A JP2022578618A JP7644151B2 JP 7644151 B2 JP7644151 B2 JP 7644151B2 JP 2022578618 A JP2022578618 A JP 2022578618A JP 2022578618 A JP2022578618 A JP 2022578618A JP 7644151 B2 JP7644151 B2 JP 7644151B2
Authority
JP
Japan
Prior art keywords
sequence
seq
antigen
antibody
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022578618A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023531920A5 (enExample
JP2023531920A (ja
Inventor
ダン・ルー
ジャンナ・ポロンスカヤ
ズー－ペイ・チャン
ステラ・エー・マルトモ
ジーガー・パテル
ファイカル・ミヤラ
Original Assignee
カドモン コーポレイション，リミティド ライアビリティ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カドモン コーポレイション，リミティド ライアビリティ カンパニー filed Critical カドモン コーポレイション，リミティド ライアビリティ カンパニー
Publication of JP2023531920A publication Critical patent/JP2023531920A/ja
Publication of JP2023531920A5 publication Critical patent/JP2023531920A5/ja
Priority to JP2025028465A priority Critical patent/JP2025091418A/ja
Application granted granted Critical
Publication of JP7644151B2 publication Critical patent/JP7644151B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2022578618A 2020-06-23 2021-06-23 抗ｐｄ－１抗体および融合タンパク質 Active JP7644151B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025028465A JP2025091418A (ja) 2020-06-23 2025-02-26 抗ｐｄ－１抗体および融合タンパク質

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063043114P 2020-06-23 2020-06-23
US63/043,114 2020-06-23
US202063111459P 2020-11-09 2020-11-09
US63/111,459 2020-11-09
PCT/US2021/038740 WO2021262880A2 (en) 2020-06-23 2021-06-23 Anti-pd-1 antibodies and fusion proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025028465A Division JP2025091418A (ja) 2020-06-23 2025-02-26 抗ｐｄ－１抗体および融合タンパク質

Publications (3)

Publication Number Publication Date
JP2023531920A JP2023531920A (ja) 2023-07-26
JP2023531920A5 JP2023531920A5 (enExample) 2024-12-24
JP7644151B2 true JP7644151B2 (ja) 2025-03-11

Family

ID=79282816

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022578618A Active JP7644151B2 (ja) 2020-06-23 2021-06-23 抗ｐｄ－１抗体および融合タンパク質
JP2025028465A Pending JP2025091418A (ja) 2020-06-23 2025-02-26 抗ｐｄ－１抗体および融合タンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025028465A Pending JP2025091418A (ja) 2020-06-23 2025-02-26 抗ｐｄ－１抗体および融合タンパク質

Country Status (13)

Country Link
US (4) US20230416363A1 (enExample)
EP (3) EP4729531A3 (enExample)
JP (2) JP7644151B2 (enExample)
KR (1) KR20230027267A (enExample)
CN (1) CN116194471A (enExample)
AU (1) AU2021296437A1 (enExample)
BR (1) BR112022025632A2 (enExample)
CA (1) CA3184746A1 (enExample)
CO (1) CO2022018053A2 (enExample)
IL (1) IL299238A (enExample)
MX (1) MX2022016588A (enExample)
PH (1) PH12022500029A1 (enExample)
WO (1) WO2021262880A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116194471A (zh) 2020-06-23 2023-05-30 卡德门企业有限公司 抗pd-1抗体和融合蛋白
CN116333155A (zh) * 2023-03-09 2023-06-27 杭州美赛生物医药科技有限公司 靶向pd-1和vegf的双功能抑制剂
WO2025048616A1 (ko) * 2023-08-31 2025-03-06 주식회사 지아이셀 Il-2 단백질 및 il-15 단백질의 키메라 단백질 또는 변이체, 이를 포함하는 융합단백질, 및 이를 발현하는 유전자 조작된 세포
WO2025217310A1 (en) * 2024-04-10 2025-10-16 Prolynx Llc Pegylated il- 15 receptor alpha cytokines
WO2026158432A1 (zh) * 2025-01-24 2026-07-30 江苏奥赛康生物医药有限公司 抗pd-1抗体-il-15前药的融合分子与化学治疗药物的组合及其应用
WO2026161860A1 (en) * 2025-01-27 2026-07-30 Kadmon Corporation, Llc Dosing of immunocytokines for cancer treatment

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019204665A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
JP2019533443A (ja) 2016-10-14 2019-11-21 ゼンコア インコーポレイテッド ＩＬ１５／ＩＬ１５Ｒαヘテロ二量体ＦＣ−融合タンパク質
WO2020077276A2 (en) 2018-10-12 2020-04-16 Xencor, Inc. Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
ATE329263T1 (de) * 1998-10-30 2006-06-15 Jonathan L Miller Regionen variabler schwerer ketten und variabler leichter ketten von antikörpern für humanes blutplättchen-glykoprotein ib alpha
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
GB0816461D0 (en) * 2008-09-09 2008-10-15 Univ Manchester Biomass
WO2011130417A2 (en) * 2010-04-15 2011-10-20 Amgen Inc. HUMAN FGF RECEPTOR AND β-KLOTHO BINDING PROTEINS
JP6251570B2 (ja) * 2010-09-21 2017-12-20 アルター・バイオサイエンス・コーポレーション 多量体ｉｌ−１５可溶性融合分子並びにその製造及び使用方法
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
LT2748201T (lt) * 2011-08-23 2018-02-26 Roche Glycart Ag Dvigubai specifinė t ląsteles aktyvinantį antigeną surišanti molekulė
HK1200850A1 (en) * 2011-09-23 2015-08-14 罗氏格黎卡特股份公司 Bispecific anti-egfr/anti igf-1r antibodies
WO2014023709A1 (en) * 2012-08-09 2014-02-13 Roche Glycart Ag Asgpr antibodies and uses thereof
EP3027649B1 (en) * 2013-08-01 2020-04-01 F.Hoffmann-La Roche Ag Tnfa-il-17 bispecific antibodies
US8945560B1 (en) * 2014-07-15 2015-02-03 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
LT3094351T (lt) * 2014-01-15 2022-04-11 Kadmon Corporation, Llc Imunitetą moduliuojantys agentai
JP6996979B2 (ja) * 2015-03-31 2022-02-04 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 三量体ｔｎｆファミリーリガンドを含む抗原結合分子
AU2016326575A1 (en) * 2015-09-25 2018-04-12 Altor Bioscience Corporation Interleukin-15 superagonist significantly enhances graft-versus-tumor activity
EP3455254B1 (en) * 2016-05-11 2021-07-07 F. Hoffmann-La Roche AG Antigen binding molecules comprising a tnf family ligand trimer and a tenascin binding moiety
KR102048476B1 (ko) * 2016-08-05 2019-11-26 주식회사 와이바이오로직스 프로그램화된 세포 사멸 단백질(pd-1)에 대한 신규 항체 및 이의 용도
LT3535298T (lt) * 2016-11-02 2021-12-27 Jounce Therapeutics, Inc. Antikūnai prieš pd-1 ir jų panaudojimas
AU2018291497A1 (en) * 2017-06-30 2020-01-16 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains
GB201803745D0 (en) * 2018-03-08 2018-04-25 Ultrahuman Eight Ltd PD1 binding agents
CN116194471A (zh) 2020-06-23 2023-05-30 卡德门企业有限公司 抗pd-1抗体和融合蛋白

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019533443A (ja) 2016-10-14 2019-11-21 ゼンコア インコーポレイテッド ＩＬ１５／ＩＬ１５Ｒαヘテロ二量体ＦＣ−融合タンパク質
WO2019204665A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
WO2020077276A2 (en) 2018-10-12 2020-04-16 Xencor, Inc. Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof

Also Published As

Publication number Publication date
CA3184746A1 (en) 2021-12-30
EP4610275A3 (en) 2025-12-03
EP4168124A2 (en) 2023-04-26
US12612460B2 (en) 2026-04-28
IL299238A (en) 2023-02-01
CO2022018053A2 (es) 2022-12-20
US20250136693A1 (en) 2025-05-01
US20260176362A1 (en) 2026-06-25
US20230416363A1 (en) 2023-12-28
JP2025091418A (ja) 2025-06-18
PH12022500029A1 (en) 2024-04-22
MX2022016588A (es) 2023-03-15
WO2021262880A2 (en) 2021-12-30
AU2021296437A1 (en) 2023-02-23
BR112022025632A2 (pt) 2023-01-17
US20260217831A1 (en) 2026-07-30
KR20230027267A (ko) 2023-02-27
EP4729531A2 (en) 2026-04-22
EP4610275A2 (en) 2025-09-03
WO2021262880A3 (en) 2022-02-17
EP4729531A3 (en) 2026-07-15
CN116194471A (zh) 2023-05-30
EP4168124A4 (en) 2024-10-02
JP2023531920A (ja) 2023-07-26

Similar Documents

Publication Publication Date Title
JP7587656B2 (ja) Ｐｄ－ｌ１及びｃｄ１３７に結合する抗体分子
JP7701964B2 (ja) Ｃｄ１３７及びｏｘ４０に結合する抗体分子
JP7603205B2 (ja) 抗体分子
JP7489316B2 (ja) Ｐｄ－ｌｉ抗原結合部位を有するｆｃ結合断片
US12612460B2 (en) Anti-PD-1 antibodies and fusion proteins
BR112020026862A2 (pt) antagonistas antitumorais de reguladores de pontos de verificação imunológica
US12391764B2 (en) Anti-CD30 and anti-CD3 bispecific antibodies and methods of immunotherapy for CD30+ malignancies
WO2023186112A1 (zh) 靶向ceacam和cd3的多特异性抗体及其用途
RU2861719C2 (ru) Антитела к pd-1 и слитые белки
US12559556B1 (en) BCMA × CD3 T bispecific cell engager
CN120230216B (zh) 抗lair1抗体及其用途
US20230312724A1 (en) B7-H4 Antibodies and Anti-B7-H4 Antibody/IL-15 Fusion Proteins

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240621

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240621

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241216

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20241216

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250128

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250227

R150 Certificate of patent or registration of utility model

Ref document number: 7644151

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150